Last reviewed · How we verify
Byetta (Exenatide)
Exenatide mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion in response to blood glucose elevation and suppress glucagon release.
Exenatide mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion in response to blood glucose elevation and suppress glucagon release. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Byetta (Exenatide) |
|---|---|
| Sponsor | Beijing Chao Yang Hospital |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Exenatide is a GLP-1 receptor agonist that binds to GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also slows gastric emptying and promotes satiety, leading to reduced food intake and improved glycemic control. The drug is effective only when blood glucose levels are elevated, reducing hypoglycemia risk.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Hypoglycemia
- Injection site reactions
Key clinical trials
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- Exenatide For Reducing the Reinforcing Effects of Cocaine (PHASE1)
- GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (PHASE2)
- Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome (PHASE3)
- Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) (PHASE4)
- A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Byetta (Exenatide) CI brief — competitive landscape report
- Byetta (Exenatide) updates RSS · CI watch RSS
- Beijing Chao Yang Hospital portfolio CI